Key result
Preoperative use of ACEi or ARBs in patients undergoing colorectal surgery was not associated with a significantly increased risk of postoperative acute kidney injury compared to non-users (61.0% vs 56.7%, p=0.35).
Why the study?
Surgical patients taking ACEi or ARB are susceptible to intraoperative hypotension-related complications, and perioperative continuation in colorectal surgery may cause more harm than benefit due to additional hypotension risk factors.
Does taking ACEi/ARB before surgery increase the risk of acute kidney injury and perioperative morbidity in adult patients undergoing colorectal surgery?
Cohort (n=1,020)
No
Does taking ACEi/ARB before surgery increase the risk of acute kidney injury and perioperative morbidity in adult patients undergoing colorectal surgery?
Absolute Event Rate: 61% vs 56.7%
p-value: p=0.35
Perioperative use of ACEi/ARB in colorectal surgery appears safe regarding AKI and mortality, though it increases the need for intraoperative vasopressors.
Continuation of ACEi/ARB may increase intraoperative hypotension risk in colorectal surgery; leaves open whether discontinuation improves outcomes in prospective trials.
Patients undergoing surgery and taking angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) are susceptible to complications related to intraoperative hypotension. Perioperative continuation of such medications in patients undergoing colorectal surgery may be associated with more harm than benefit, as these patients are often exposed to other risk factors which may contribute to intraoperative hypotension. Our objectives were to assess the incidence and severity of postinduction hypotension as well as the rates of acute kidney injury (AKI), 30-day all-cause mortality, 30-day readmission, and hospital length of stay in adult patients undergoing colorectal surgery who take ACEi/ARB.We performed a retrospective chart review of patients undergoing colorectal surgery of ≥4 hour duration at a tertiary care academic medical center between January 2011 and November 2016. The preoperative and intraoperative characteristics as well as postoperative outcomes were compared between patients taking ACEi/ARB and patients not taking these medications.Of the 1020 patients meeting inclusion criteria, 174 (17%) were taking either ACEi or ARB before surgery. Patients taking these medications were more likely to receive both postinduction and intraoperative phenylephrine and ephedrine. The incidences of postoperative AKI (P = .35), 30-day all-cause mortality (P = .36), 30-day hospital readmission (P = .45), and hospital length of stay (P = .25), were not significantly different between the 2 groups.Our results support the current recommendation that ACEi/ARB use is probably safe within the colorectal surgery population during the perioperative period. Intraoperative hypotension should be expected and treated with vasopressors.
No takes yet. Share an insight, caveat, or question.
Bonavia et al. (2019) conducted a cohort in Colorectal surgery (n=1,020). Angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) vs. Not taking ACEi/ARB was evaluated on Acute kidney injury (AKI) by KDIGO criteria within 48 hours following surgery (p=0.35). Preoperative use of ACEi or ARBs in patients undergoing colorectal surgery was not associated with a significantly increased risk of postoperative acute kidney injury compared to non-users (61.0% vs 56.7%, p=0.35).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: